Alcon reports financial results
Alcon has reported its financial results for the 3- and 9-month periods ending September 30, 2024, demonstrating a 6 percent increase in sales to $2.4 billion on a reported and constant currency basis for the third quarter, as compared with the same quarter of the previous year. Sales for the first nine months of 2024 were a reported $7.4 billion, an increase of 5 percent on a reported basis and 6 percent on a constant currency basis, compared with the first nine months of 2023.
The company posited that slower market conditions in the U.S. impacted the surgical division in the third quarter, which posted a slower than expected 5 percent rise in sales. Alcon also saw slight headwinds in its vision care division due to declines in contact lens sales in its international markets. Overall in the third quarter, however, contact lenses net sales were a reported $664 million, an increase of 8 percent.
As a result, Alcon said it lowered its 2024 sales forecast from a range of $9.9 billion to $10.1 billion to a range of $9.8 billion to $9.9 billion following weaker-than-expected U.S. sales in the third quarter. The company also indicated it will be launching several new products in 2025. Additionally, Alcon recently released Precision7, its first one-week replacement contact lens, in the U.S. during the fourth quarter.
